Skip to main content
. 2020 Aug 12;10:1261. doi: 10.3389/fonc.2020.01261

Figure 2.

Figure 2

The prognostic value of DDX39 overexpression in melanoma patients. The overall survival time was counted from the day of operation to the end of follow-up. The disease-free survival time was counted from the date of surgery to the time of disease recurrence or metastasis. (A) Patients with a higher expression of DDX39 had a shorter disease-free survival time. (B) Patients with a higher expression of DDX39 also had a shorter overall survival time.